 |
O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1yl]diazen-1-ium-1,2-diolate |
|---|---|
| Trade Name | |
| Orphan Indication | Multiple myeloma |
| USA Market Approval | USA |
| USA Designation Date | 2013-12-13 00:00:00 |
| Sponsor | JSK Therapeutics, Inc.;85 Fort Douglas Boulevard, P.O. Box 58986;Salt Lake City, Utah, 84158 |
Related Access Program
AbbVie – Multiple Myeloma
Janssen Research & Development, LLC – Multiple Myeloma
Dana-Farber Cancer Institute – Multiple Myeloma
Bristol-Myers Squibb – Multiple Myeloma
Peking University – Multiple Myeloma
Novartis Pharmaceuticals – Multiple Myeloma
Onyx Pharmaceuticals, Inc., an Amgen subsidiary – Multiple myeloma